ENGLEWOOD CLIFFS, N.J., Feb. 13 /PRNewswire-FirstCall/ -- EpiCept Corporation announced today that Jack Talley, CEO, will present as part of a panel entitled, “Cure the Pain,” at the BIO CEO & Investor Conference on Tuesday, February 14, 2006 at 4:00 p.m., ET, in the Basildon Room at The Waldorf-Astoria, New York, NY.
(Logo: http://www.newscom.com/cgi-bin/prnh/20020513/NYM112LOGO )
Mr. Talley will join a distinguished group of panelists who will share their insights on the latest developments related to the search for greater safety and efficacy in pain relief. The presentation will be available via webcast beginning on February 15 and can be viewed on the BIO website at: http://ceo.bio.org/opencms/ceo/2006/index.jsp. The presentation will be archived for 90 days on the BIO website.
About EpiCept Corporation
EpiCept is an emerging pharmaceutical company focused on unmet needs in the treatment of pain and cancer. The company has a staged portfolio with several pain therapies in late-stage clinical trials, and a lead oncology compound (for AML) with demonstrated efficacy in a Phase III trial; the compound is intended for commercialization in Europe. EpiCept is based in New Jersey, and the company’s R&D team in San Diego is pursuing a drug discovery program focused on novel approaches to apoptosis.
Contact: Robert W. Cook EpiCept Corporation 201-894-8980 rcook@epicept.com Lev Janashvili Feinstein Kean Healthcare 617-761-6731 lev.janashvili@fkhealth.com EPCT - GEN
Photo: NewsCom: http://www.newscom.com/cgi-bin/prnh/20020513/NYM112LOGOAP Archive: http://photoarchive.ap.orgPRN Photo Desk, +1-888-776-6555 or +1-212-782-2840EpiCept Corporation
CONTACT: Robert W. Cook of EpiCept Corporation, +1-201-894-8980,rcook@epicept.com; or Lev Janashvili of Feinstein Kean Healthcare,+1-617-761-6731, lev.janashvili@fkhealth.com, for EpiCept Corporation
